Clinical trials: Acute Granulocytic Leukemia
Acute Myeloid Leukemia
Venetoclax Registry
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax
- Trial name
- VENreg (NCT03662724)
- Testing
- Venetoclax
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannover Medical School
Leukemia, Lymphoma
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003079
- Testing
- bryostatin 1, cytarabine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Acute Myeloid Leukemia
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
The purpose of this study is to determine whether tigecycline is safe and which dosage is most effective in the treatment of patients with acute myeloid leukemia.
- Trial name
- NCT01332786
- Testing
- Tigecycline
- Where
- 3 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
This trial is a single-center, non-blind, two-arm randomized prospective controlled trial to compare the effectiveness of two induction chemotherapy regimens (high-dose cytarabine plus daunorubicin [HDAC] vs.
- Trial name
- NCT03507842
- Testing
- High dose Cytarabine, Cytarabine, Hign dose Daunorubicin
- Where
- South Korea
- Volunteers
- 380 people
- Sponsor
- Asan Medical Center
Relapsed Adult AML, Stem Cell Transplant Complications
Menin-Inhibitor Targeted Maintenance in AML
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML.
- Conditions
- Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
- Trial name
- NCT07563010
- Testing
- Revumenib
- Volunteers
- 146 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.
- Trial name
- NCT07264010
- Testing
- Sorafenib (SORA), Venetoclax (VEN)
- Volunteers
- 87 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Leukemia
Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00739388
- Testing
- azacytidine
- Where
- 11 sites in Switzerland
- Volunteers
- 47 people
- Sponsor
- Swiss Cancer Institute
Acute Myeloblastic Leukemia, Acute Lymphoblastic Leukemia
Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia
The radio-labeled anti-CD66 monoclonal antibody (with 111In for dosimetry and 90Y for therapy) will be administered in the T11 North room, UCLH, while the reduced intensity conditioning regimen and the allogeneic hematopoietic…
- Conditions
- Acute Myeloblastic Leukemia, Acute Lymphoblastic Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT04082286
- Testing
- Yttrium-90 labelled monoclonal antibody against CD66
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Background: Stem cell transplantation from a partially matched donor can lead to graft-versus-host disease (GVHD). Researchers want to learn how to improve these transplantations.
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02226861
- Testing
- CliniMACS CD34 selection system, ULD IL-2
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
AML, Childhood, Relapse/Recurrence
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.
- Conditions
- AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
- Trial name
- NCT06316960
- Testing
- Avapritinib, Azacitidine Injection, Decitabine Injection
- Where
- 12 sites in China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Soochow University
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL
Hypothesis: Myeloablative conditioning using a dose escalation of clofarabine in combination with cytarabine (ARA-C) and total body irradiation (TBI) will lead to improved survival for previously untransplanted children and…
- Trial name
- NCT00529360
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- New York Medical College
Acute Myeloid Leukemia
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)…
- Trial name
- NCT06672146
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 138 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndromes
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over a longer period of time are as well…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00005823
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Leukemia Research Fund
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
This phase I clinical trial is studies the side effects and best dose of giving veliparib together with temozolomide in treating patients with acute leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT01139970
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
- Trial name
- NCT04233346
- Testing
- Ponatinib 30mg OD, Ponatinib 45mg OD
- Where
- 14 sites in China
- Volunteers
- 93 people
- Sponsor
- Otsuka Beijing Research Institute
Leukemia
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow…
- Trial name
- NCT00006240
- Testing
- sargramostim, dexamethasone, oral sodium phenylbutyrate
- Where
- 4 sites in United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematologic Malignancies, Acute Leukemia
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
This is a research study involving the treatment of patients with hematological cancers with allogeneic (cells from a donor) hematopoietic stem cell transplant (HSCT). HSCT is often referred to as bone marrow transplant.
- Conditions
- Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes, Hodgkin's Lymphoma
- Trial name
- NCT01350258
- Testing
- Fludarabine, Thiotepa, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemias
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone.
- Trial name
- REVEAL-ND NPM1 (NCT07211958)
- Testing
- Revumenib, Intensive Chemotherapy Regimen
- Where
- 173 sites in United States, Argentina and 21 more
- Volunteers
- 468 people
- Sponsor
- Syndax Pharmaceuticals
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of rebeccamycin analog in treating patients with relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or chronic…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00087204
- Testing
- becatecarin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
This pilot clinical trial studies mechanical stimulation in preventing bone density loss in patients undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01558778
- Testing
- management of therapy complications, musculoskeletal complications management/prevention
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.